ROCKVILLE, Md., March 6, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the following March investor conferences:
Morgan Stanley Healthcare Corporate Access Day
Date: Tuesday, March 19, 2019
Location: Boston Harbor Hotel at Rowes Wharf, Boston, MA
About REGENXBIO
CONTACT:
Investors:
Heather Savelle, 212-600-1902
[email protected]
Media:
David Rosen, 212-600-1902
[email protected]
SOURCE REGENXBIO Inc.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.

